Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea

Drug lag—delayed approval or reimbursement—is a major barrier to accessing cutting‐edge drugs. Unlike approval lag, reimbursement lag is under‐researched. We investigated the key determinants of reimbursement lag under Taiwan National Health Insurance (NHI), and compared this lag with those in the U...

Descripción completa

Detalles Bibliográficos
Autores principales: Shih, Yi‐Ru, Liao, Kai‐Hsin, Chen, Yen‐Hui, Lin, Fang‐Ju, Hsiao, Fei‐Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485943/
https://www.ncbi.nlm.nih.gov/pubmed/32166908
http://dx.doi.org/10.1111/cts.12778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485943/
https://www.ncbi.nlm.nih.gov/pubmed/32166908
http://dx.doi.org/10.1111/cts.12778

Ejemplares similares